Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

NCT04510415 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study termination by the Sponsor

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Olmutinib

Sponsor

Hanmi Pharmaceutical Company Limited